COVID-19: Ryukyu University develops therapeutic drug for COVID-19: administers “colchicine”
Ryukyu University
Yokohama City University
Jointly, we will start doctor-led clinical trials nationwide.
We will develop a drug to prevent the aggravation of COVID-19.
Administer “colchicine”:
In a doctor-initiated clinical trial, colchicine, which has already been approved by the regulatory affairs, will be administered to COVID-19 patients.
“Colchicine” is being used as a remedy for gout.
We will verify the preventive effect of the new corona aggravation.
Research background:
Colchicine is an alkaloid contained in the autumn crocus.
In Japan, gout and familial Mediterranean fever are indicated as anti-inflammatory drugs.
Ryukyu University:
A cohort study is underway in patients with diabetic coronary artery disease who are at high risk of becoming severe with COVID-19.
The effect of colchicine on improving endothelial function has been confirmed in patients with coronary artery disease with enhanced inflammatory response.
Research content:
Even moderate and mild in hospital
For COVID-19 patients with aggravating factors
Phase II of colchicine,
Randomization,
Double blind,
Placebo control,
Multi-facility joint,
Parallel group-to-group trials
It will be conducted as a doctor-led clinical trial.
YCU Yokohama City University
https://www.yokohama-cu.ac.jp/news/2020/20201105_yamanaka.html
Colchicine: Suppresses exacerbations in COVID-19 patients?
Colchicine:
It has an anti-inflammatory effect with a mechanism different from that of steroids and NSAIDs, and is used for the treatment of gout.
When a gout attack relapses:
Administration of colchicine suppresses neutrophil chemotaxis and response to vascular injury,
Inhibiting inflammasome signaling
Suppresses the production of interleukin-1β,
Neutrophil-platelet interaction and agglutination,
It has been reported to suppress.
Colchicine and COVID-19:
Considering that it may be an effective and safe treatment for inflammation,
16 tertiary medical institutions in Greece:
We decided to carry out the open label GReek Study in the Effects of Colchicine in Covid-19 Complications Prevention (GRECCO-19).
Nikkei Medical
https://medical.nikkeibp.co.jp/leaf/mem/pub/report/t344/202007/566360.html